Background The first HPV vaccines licensed targeted two HPV types responsible for most cervical cancers. A 9-valent vaccine (9vHPV), targeting 5 additional types, was introduced in 2016 and is currently the only HPV vaccine available in the United States. Previous studies demonstrated high rates of HPV infection in Alaska Native (AN) women. We sought to measure prevalence of high risk HPV types in AN women undergoing colposcopy and to determine those preventable by vaccination. Methods For this cross-sectional study, we recruited women who were undergoing colposcopy for clinical indications at Alaska Native Medical Center to obtain cervical brush biopsy samples. Specimens were shipped to Atlanta, Georgia for DNA extraction, HPV detection, and typing using L1 PCR with type-specific hybridization to detect 37 HPV types. Results Four hundred eighty eight specimens from 489 women were tested. At least one HPV type was found in 458 (94%) specimens. Of 458 participants who were HPV positive, 332 (72%) had two or more types. At least one type targeted by 9vHPV was detected in 95% of participants with CIN 3 (21/22), 82% with CIN 2 (37/45), and 65% with CIN 1 (119/184). ( p < 0.001) HPV 16 or 18 were detected in 77% (17/22) with CIN 3, 53% (24/45) with CIN 2, and 36% (67/184) with CIN 1. ( p < 0.001). Conclusions A substantial proportion of AN women attending colposcopy clinic had evidence of HPV 16/18 infection, as well as other high risk types targeted by 9vHPV. At least one 9vHPV type was detected in 62% of the participants overall, and 95% of participants with CIN3. AN women are expected to benefit from vaccination against HPV 16/18, and will have greater benefit from 9vHPV. Information from this study could be used to develop public health strategies to increase vaccine uptake, or to track HPV genotype prevalence over time.

中文翻译：

---

2009-2011 年在阿拉斯加安克雷奇参加阴道镜检查诊所的阿拉斯加土著妇女中的人乳头瘤病毒 (HPV) 类型

背景 第一个获得许可的 HPV 疫苗针对导致大多数宫颈癌的两种 HPV 类型。一种针对另外 5 种类型的 9 价疫苗 (9vHPV) 于 2016 年推出，是目前美国唯一可用的 HPV 疫苗。先前的研究表明，阿拉斯加原住民 (AN) 女性的 HPV 感染率很高。我们试图测量接受阴道镜检查的 AN 女性中高​​危 HPV 类型的患病率，并确定可通过疫苗接种预防的人群。方法 对于这项横断面研究，我们招募了在阿拉斯加土著医学中心接受阴道镜检查临床适应症的女性，以获取宫颈刷活检样本。样本被运送到佐治亚州亚特兰大进行 DNA 提取、HPV 检测，并使用 L1 PCR 和类型特异性杂交进行分型，以检测 37 种 HPV 类型。结果 对来自 489 名女性的 488 份样本进行了测试。在 458 个 (94%) 样本中发现了至少一种 HPV 类型。在 458 名 HPV 阳性的参与者中，332 名（72%）有两种或两种以上类型。在 95% 的 CIN 3 (21/22) 参与者、82% 的 CIN 2 (37/45) 和 65% 的 CIN 1 (119/184) 参与者中检测到至少一种 9vHPV 靶向类型。( p < 0.001) 77% (17/22) 的 CIN 3、53% (24/45) 的 CIN 2 和 36% (67/184) 的 CIN 1 检测到 HPV 16 或 18。 ( p < 0.001 ）。结论 大部分就诊阴道镜检查的 AN 女性有 HPV 16/18 感染的证据，以及 9vHPV 靶向的其他高危类型。62% 的参与者和 95% 的 CIN3 参与者至少检测到一种 9vHPV 类型。预计 AN 妇女将从接种 HPV 16/18 疫苗中受益，并且将从 9vHPV 中获得更大的益处。该研究的信息可用于制定公共卫生战略以增加疫苗接种率，或跟踪 HPV 基因型随时间的流行情况。